Blue Cross Blue Shield of Massachusetts returned to profitability in the first quarter of 2026, posting a net income of $59.6 million on $2.6 billion in revenue. For the company’s CFO, Ruby Kam, the result was meaningful, but one worth keeping in perspective.
“One quarter does not make a year,” Ms. Kam told Becker’s, projecting the company will likely finish 2026 at a loss.
“We are doing everything we can to pull ourselves into the black starting in 2027,” she said. “There is a lot of uncertainty. Reimbursement rates, Medicare Advantage policy, potential tariffs on drugs, volatility in the stock market affecting our portfolio returns, and the stability of employment in Massachusetts all come into play.”
The positive Q1 results come after a tough two-year stretch for the nonprofit insurer, which posted a $222.8 million loss in 2025 following a $223.6 million loss in 2024. The most recent earnings were driven by a combination of factors, including disciplined cost management, a milder-than-expected flu season, three major snowstorms that kept members out of care settings, and the company’s decision last year to drop GLP-1 coverage for weight loss. Spending on the drug class had escalated from roughly $140 million in 2023 to more than $500 million in 2025. Without the coverage change, Ms. Kam said it would have approached $1 billion this year.
“It’s always about trying to find balance with whatever decision we make,” she said. “How hard do you pull a lever, what are the potential consequences, and is it worth it?”
Across the industry, insurers have reported elevated utilization rates and a corresponding rise in costs for nearly three years. Within the Blues ecosystem alone, individual plans and larger parent organizations alike posted massive losses in 2025 amid spending that continues to outpace premium revenue.
“It’s a debate that folks in the industry are talking about, and I don’t think there’s a clear-cut answer, even for folks that have decades of experience,” Ms. Kam said.
On one side of the argument, she said, are those who view the current environment as a painful but familiar underwriting cycle, and one the industry will work its way through as plans reprice, cut costs and tighten benefits. On the other are those who believe something structural has changed and that today’s environment is genuinely different from prior cycles.
Ms. Kam, who spent nearly two decades at UnitedHealth Group before joining BCBS, said she sees evidence for both views. But the factors that give her pause about the “it’s just a cycle” argument include the lingering effects of COVID and questions around labor shortages.
Perhaps most of all, AI has been disruptive in ways that go beyond what the industry has navigated before, including its role in accelerating provider coding intensity, which BCBS Massachusetts has moved to address through expanded claims reviews. The BCBS Association has even tried to quantify it, releasing research in March that estimated AI-enabled coding tools may be driving more than $2 billion in excess spending annually across inpatient and outpatient settings.
What plans can do in the meantime, Ms. Kam said, is focus on the factors within their control while trying to hold the balance between cost discipline and mission. For BCBS Massachusetts, that’s included offering voluntary separations to roughly 18% of its workforce, consolidating real estate, and renegotiating vendor contracts.
“As trend goes up, we need to cover our costs, and so our pricing has to go up,” Ms. Kam said. “It could get to a point where there are clients that opt out of healthcare, and that’s not a place that we want to be.”
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
